Author: | Sadelain, M. |
Article Title: | RORing T cells target CLL and MCL |
Abstract: | Genetically targeted T lymphocytes are emerging as powerful antitumor agents. Their rapid generation, made possible by robust and clinically applicable gene transfer technologies, provides a novel means to circumvent immune tolerance and generate tumor-reactive T cells on demand. Thus, patient peripheral blood T cells can be readily redirected toward any chosen antigen, including tumor antigens which are for the most part "self" antigens, and infused to promptly raise the number of tumor-reactive T cells without requiring active immunization and without the risk of deleterious alloreactivity (as may be the case after donor leukocyte infusion or non-T cell-depleted bone marrow transplantation). |
Keywords: | unclassified drug; note; protein domain; t lymphocyte; cell survival; gene targeting; mantle cell lymphoma; cell differentiation; antineoplastic activity; cytotoxicity; acute lymphoblastic leukemia; b lymphocyte; gene transfer; t lymphocyte receptor; immunological tolerance; nonhodgkin lymphoma; carbonate dehydratase ix; genetic engineering; antigen specificity; cancer cell; antigen recognition; retrovirus vector; hematopoietic cell; chimeric antigen receptor; donor lymphocyte infusion; target cell; melan a; bone marrow transplantation; chronic lymphatic leukemia; wnt protein; hla antigen; cd19 antigen; lymphocyte antigen receptor; lymphocyte function; fetus development; peripheral lymphocyte; frizzled protein; alloimmunity; ror1 protein; active immunization; kringle domain |
Journal Title: | Blood |
Volume: | 116 |
Issue: | 22 |
ISSN: | 0006-4971 |
Publisher: | American Society of Hematology |
Date Published: | 2010-11-25 |
Start Page: | 4387 |
End Page: | 4388 |
Language: | English |
DOI: | 10.1182/blood-2010-09-303388 |
PROVIDER: | scopus |
PUBMED: | 21109622 |
DOI/URL: | |
Notes: | --- - "Export Date: 20 April 2011" - "CODEN: BLOOA" - "Source: Scopus" |